Anticoagulant Reversal Drug Pulled From U.S. Market

(MedPage Today) — Andexanet alfa (Andexxa) will officially be taken off the U.S. market this month as an emergency reversal medication for contemporary blood thinners.
“The Biologics License Application for Andexxa has been withdrawn for commercial…

Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119001

Author :

Publish date : 2025-12-12 22:22:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Anticoagulant Reversal Drug Pulled From U.S. Market

Myasthenia Gravis Gets a New Drug Approval

CDC Says Kids’ COVID Shots Reduced Emergency Department Visits

Related Posts

Survival Is Possible With Resuscitation in Some Extremely Premature Infants

CDC Says Kids’ COVID Shots Reduced Emergency Department Visits

Myasthenia Gravis Gets a New Drug Approval

The King’s Cancer Speech; Multiple Studies Retracted; Mass Sperm Donor Had TP53 Gene

Lowering FDA’s Drug-Approval Standards Is a Lose-Lose

More Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast Cancer

Survival Is Possible With Resuscitation in Some Extremely Premature Infants

CDC Says Kids’ COVID Shots Reduced Emergency Department Visits

Anticoagulant Reversal Drug Pulled From U.S. Market

Myasthenia Gravis Gets a New Drug Approval

The King’s Cancer Speech; Multiple Studies Retracted; Mass Sperm Donor Had TP53 Gene

Lowering FDA’s Drug-Approval Standards Is a Lose-Lose

More Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast Cancer

What Trump’s Cognitive Tests Can — and Can’t — Reveal

Categories

Archives